Arcutis Biotherapeutics (ARQT) Common Equity (2019 - 2026)

Arcutis Biotherapeutics' Common Equity history runs 8 years deep, the most recent figure standing at $189.6 million for Q1 2026.

• In Q1 2026, Common Equity rose 32.94% year-over-year to $189.6 million; the TTM figure through Mar 2026 stood at $189.6 million (up 32.94% YoY), while the FY2025 annual figure was $189.5 million, up 20.27% from the prior year.
• Common Equity for Q1 2026 stood at $189.6 million, roughly flat from $189.5 million in the prior quarter.
• The five-year high for Common Equity was $270.8 million in Q3 2022, with the low at $46.7 million in Q3 2023.
• The 5-year median for Common Equity is $158.1 million (2025), against an average of $166.4 million.
• The sharpest annual moves came in 2023 and 2024: Common Equity plunged 82.75% in 2023, then soared 235.3% in 2024.
• Arcutis Biotherapeutics' Common Equity stood at $209.6 million in 2022, then plunged by 57.69% to $88.7 million in 2023, then surged by 77.68% to $157.5 million in 2024, then advanced by 20.27% to $189.5 million in 2025, then advanced by 0.09% to $189.6 million in 2026.
• Business Quant data shows ARQT's Common Equity at $189.6 million in Q1 2026, $189.5 million in Q4 2025, and $158.1 million in Q3 2025.